Smith & Nephew plc stock: Cevian Capital's massive stake acquisition signals activist push in medtech

Activist investor Cevian Capital II GP Ltd disclosed a major 81.7 million share purchase in Smith & Nephew plc (ISIN: GB0009223206) on March 12, 2026, now comprising 42% of its portfolio. This move spotlights the FTSE 100 medtech leader amid soft recent trading. German-speaking investors gain from enhanced liquidity on Xetra and potential value unlocks.

Smith & Nephew plc shares came under spotlight after activist investor Cevian Capital II GP Ltd revealed it acquired 81,687,136 shares on March 12, 2026. This stake now forms 42.45% of Cevian's portfolio, bought at $33.04 per share on the NYSE in USD. The disclosure underscores confidence in the UK medtech firm's turnaround potential despite year-to-date price softness.

As of: 21.03.2026

By Dr. Elena Hargrove, Senior Medtech Analyst – Tracking activist interventions in European healthcare leaders like Smith & Nephew to uncover value for continental investors.

Activist Stake Ignites Interest in Smith & Nephew

Cevian Capital, known for steering portfolio companies toward higher performance, entered Smith & Nephew with conviction. The purchase represents 9.60% of Cevian's total investments, valued at roughly $3.66 billion overall. This positions the London-listed medtech as Cevian's top holding, surpassing names like Autoliv and UBS Group.

The timing aligns with Smith & Nephew's ongoing recovery from pandemic disruptions. Orthopedics, contributing 41% of revenues, has shown resilience, bolstered by sports medicine (30%) and wound care (29%). Over half of sales stem from the US, providing dollar exposure beneficial for DACH portfolios amid euro weakness.

For DACH investors, this activist entry matters now. Smith & Nephew trades on Xetra in EUR, offering direct access without FX hurdles. Cevian's involvement could catalyze strategic reviews, echoing past successes in industrial and financial sectors.

Markets reacted cautiously, with the NYSE-listed shares at $31.94 in USD as of recent trading on March 20, 2026, down 1.24% that day. Year-to-date, the stock has eased 2.86%, reflecting broader medtech sector pressures from elective procedure backlogs.

Smith & Nephew's Core Strengths in Medtech

Smith & Nephew plc leads in advanced medical devices, focusing on orthopaedics, sports medicine, ear-nose-throat, and wound management. Its portfolio includes REGENETEN bioinductive implants and PICO negative pressure therapy, driving innovation in high-margin segments. The company serves developed and emerging markets, with robust US dominance ensuring stable cash flows.

Financial health remains solid, evidenced by a GF Score of 87/100. Profitability ranks 8/10, with 16.80% three-year EBITDA growth and 12.50% operating margin expansion. These metrics highlight operational leverage as procedure volumes normalize post-COVID.

Market cap hovers around $13.55 billion USD as of March 2026, placing it among the top 1520 global firms. For DACH investors, the firm's 22.30 PE ratio near its GF Value of $30.90 suggests fair pricing with upside from activist oversight.

Growth rank stands at 7/10, supported by consistent revenue expansion. The company navigates supply chain challenges effectively, maintaining utilization rates competitive in medtech.

Cevian Capital's Track Record and Strategy

Cevian Capital excels in active ownership, targeting undervalued firms with improvement potential. Based in Jersey, it manages stakes in CRH plc and others, emphasizing financial services and consumer cyclicals alongside healthcare. The firm's value-oriented approach has delivered substantial returns historically.

This Smith & Nephew bet mirrors Cevian's playbook: large positions to influence boardroom decisions. With 42.45% portfolio weight, expect pushes for cost discipline, asset reviews, or M&A acceleration. Past interventions have unlocked billions in shareholder value.

For investors, Cevian's entry signals near-term catalysts. Shares may see volatility but benefit from strategic focus. On the London Stock Exchange, primary listing for ISIN GB0009223206 trades in GBP, while NYSE ADR offers USD liquidity.

Recent Trading Dynamics and Valuation

Smith & Nephew shares on NYSE closed at $31.94 USD on March 20, 2026, after a three-day decline. Support levels cluster around $31.07, with resistance at $31.84. Dividend history shows steady payouts, latest at $0.447 per share in early 2025.

Analyst consensus leans hold, with average price target $36.75 USD, implying 13-15% upside from recent levels. High target $37.50 USD from Bernstein, low $35.00 USD. Eight holds and one buy reflect measured optimism.

PE at 22.30 appears reasonable versus medtech peers. GF Value near $30.90 USD confirms intrinsic worth alignment. DACH traders on Xetra monitor EUR equivalents closely.

Investor Relevance for DACH Portfolios

German-speaking investors find Smith & Nephew appealing via Xetra trading in EUR. The stock's FTSE 100 status ensures liquidity, while US revenue mix hedges EUR risks. Cevian's stake elevates governance scrutiny, potentially boosting dividends or buybacks.

Medtech demand grows with aging demographics in Germany, Austria, Switzerland. Smith & Nephew's orthopaedics align with rising hip/knee procedures. Exposure to emerging markets diversifies beyond Eurozone slowdowns.

Compared to local peers like Fresenius, Smith & Nephew offers purer device play without hospital ops risks. Activist pressure could narrow valuation discount to US giants like Stryker.

Sector Tailwinds and Competitive Position

Orthopaedics rebounds as elective surgeries surge. Sports medicine benefits from athlete recovery tech demand. Wound care grows via chronic disease prevalence.

Smith & Nephew differentiates through innovation like robot-assisted surgery tools. Pipeline includes next-gen implants, positioning for market share gains. US sales dominance, over 50%, captures premium pricing.

Emerging markets contribute growth, offsetting mature region flatness. Supply chain resilience post-disruptions supports margins.

Risks and Open Questions Ahead

Activist stakes introduce uncertainty; Cevian may advocate divestitures or CEO changes. Recent price softness signals procedure volume risks if recessions hit.

Regulatory hurdles in FDA approvals loom for new devices. Competition from Medtronic, Zimmer Biomet pressures pricing. Currency swings impact GBP/USD reporters.

Execution on growth targets critical. If EBITDA growth falters below 15%, sentiment sours. DACH investors watch Q1 earnings for volume clarity.

BNP Paribas added shares recently, valuing holdings at $19.7 million USD, signaling institutional interest. Yet Wall Street Zen lowered ratings, urging caution.

Overall, Cevian's bold move spotlights Smith & Nephew as a turnaround play. Diligence on activist outcomes key for positioning.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.